Irbesartan And Hydrochlorothiazide Tablet, Film Coated
Product Images NDC 72162-1035

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Irbesartan And Hydrochlorothiazide (NDC 72162-1035). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1a (Image 1)

A line graph showing the percentage of patients with systolic blood pressure under 140 mmHg plotted against baseline systolic blood pressure (mmHg). The graph includes multiple lines comparing irbesartan and hydrochlorothiazide (HCTZ) study groups, irbesartan-only groups, and HCTZ-only groups across different studies, illustrating blood pressure response trends.*

FDA Label Image

Figure 1b (Image 2)

A line graph depicting the percentage of subjects with systolic blood pressure (SBP) below 130 mmHg relative to baseline SBP in mmHg. The graph includes data from studies comparing Irbesartan and Hydrochlorothiazide (HCTZ) in different trials, showing various lines for Irbesartan and HCTZ Study V, Irbesartan Study V, HCTZ Study V, Irbesartan and HCTZ Study VI, and Irbesartan Study VI.*

FDA Label Image

Image02a (Image 3)

A line graph comparing the percentage change in diastolic blood pressure (DBP) below baseline over a range of baseline DBP values (mmHg) among different treatments in studies labeled V and VI for Irbesartan and Hydrochlorothiazide, Irbesartan alone, and Hydrochlorothiazide alone. Four distinct lines represent these groups in the graph.*

FDA Label Image

Image02b (Image 4)

A line graph showing the percentage of participants with diastolic blood pressure under 80 mmHg versus baseline diastolic blood pressure (mmHg). Multiple study lines are compared, including Irbesartan and Hydrochlorothiazide (HCTZ) Study V and VI, Irbesartan Study V and VI, and HCTZ Study V, illustrating blood pressure response across different baseline levels.*

FDA Label Image

Irbesartan Chemical Structure (Image 5)

Chemical structure of the active ingredient Irbesartan depicted as a molecular diagram showing the arrangement of rings and side chains characteristic of the molecule.*

FDA Label Image

Hctz Chemical Structure (Image 6)

Chemical structure diagram of the active ingredient, Irbesartan, showing its molecular arrangement with labeled atoms and bonds as part of the product Irbesartan and Hydrochlorothiazide.*

FDA Label Image

Figure03 (Image 7)

A scatter plot with a fitted curve depicting the relationship between Irbesartan Dose (mg/day) on the x-axis and blood pressure reduction (mmHg) on the y-axis. Data points suggest an increasing effect with dose, approaching a plateau near 600 mg/day.*

FDA Label Image

Figure04 (Image 8)

A dose-response curve graph showing the relationship between irbesartan dose (mg/day) on the x-axis and a measured variable in mmHg on the y-axis. The plot includes scattered data points and a fitted curve illustrating the dose-dependent increase up to approximately 900 mg/day.*

FDA Label Image

Label (Lbl721621035)

Label for Irbesartan and Hydrochlorothiazide Tablets, USP, 150 mg/12.5 mg film-coated tablets. The label includes storage instructions, a QR code, barcodes, and indicates the product is repackaged by Bryant Ranch Prepack, Inc. and manufactured by Pliva Hrvatska d.o.o. The package contains 90 tablets and is for oral use.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.